NORD Issues Statement on Confirmation of New FDA Commissioner, Dr. Scott Gottlieb

NORD Issues Statement on Confirmation of New FDA Commissioner, Dr. Scott Gottlieb
Washington, D.C., May 10, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement on the confirmation by the U.S. Senate of Scott Gottlieb, M.D., as Commissioner of the Food and Drug Administration (FDA):

“We at the National Organization for Rare Disorders look forward to working with Dr. Scott Gottlieb, the new Commissioner of the FDA. Dr. Gottlieb is well aware of the importance of early diagnosis of rare diseases and of the need for new treatments for the 30 million American patients with a rare disease. His insights into the issues and challenges facing the FDA and his previous service at the agency will serve him well as he assumes this important leadership position.”

There are 7,000 rare diseases that affect 200,000 or fewer Americans. The majority still have no treatment.